Pharmaceuticals

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Compa...

2022-08-18 23:46 2105

Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina, 1 in ...

2022-08-18 21:35 4413

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

* Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New...

2022-08-18 21:06 3385

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case report, titled "Long Term Complete Response of Advanced H...

2022-08-18 20:50 2809

Standigm names Carl Foster chief business officer to expand strategic partnerships for AI drug discovery

Veteran biotech and pharmaceutical executive will help company increase its growth and international impact SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, toda...

2022-08-18 20:30 2706

GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has approved the clinical trial application for GFH312 in a randomized, double-blind...

2022-08-18 19:00 2356

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: ...

2022-08-18 15:25 4346

Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

SAN FRANCISCO and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2022-08-18 08:00 4570

Picarro Introduces the First Automated Solution for Continuous Ethylene Oxide Monitoring

New system provides comprehensive solution for community monitoring stations and industrial fencelines SANTA CLARA, Calif., Aug. 17, 2022 /PRNewswire/ -- Picarro Inc., a leading gas analytics company, today announced the first comprehensive solution for monitoring ambient levels of Ethylene Oxid...

2022-08-17 22:08 3930

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults

* Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine * Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md., Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...

2022-08-17 20:00 4333

JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS

 JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15 minutes TIANJIN, China, Aug. 17, 2022 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid test kits, is proud to announce the...

2022-08-17 14:30 4828

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in seco...

2022-08-17 04:05 4659

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...

2022-08-17 01:47 6009

STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS®

Winners to Be Celebrated During Event in London on 15 October SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm was named the winner of a Gold Stevie® Award in the Pharmaceutical category and a Bronze Stevie® Award in the Computer Software category in The...

2022-08-16 20:30 3753

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022

JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022. Mr. Gang Lai, Chairman and ...

2022-08-16 20:00 3547

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership withAlbireo ...

2022-08-16 19:30 3078

Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook

- Order intake rose by almost 50 percent year-on-year, marking a new 6M-high with €4.7 billion - Sales volume increased by almost 50 percent to €3.4 billion - Adjusted EBIT increased by approximately two thirds to €202 million; adjusted EBITDA rose to €222 million, plus over 60 percent - Global...

2022-08-16 16:24 3827

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...

2022-08-16 14:48 4475

ICP DAS - BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore

TAIPEI, Aug. 16, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at MEDICAL MANUFACTURINGASIA 2022, the 5th Manufacturing Processes for Medical Technology Exhibition and Conference, which provides excellent busi...

2022-08-16 10:15 5019

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...

2022-08-16 08:30 3956
1 ... 288289290291292293294 ... 351